|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cancer stem cells in colorectal cancer from pathogenesis to therapy: Controversies and perspectives显示文摘Colorectal cancer remains one of the most common and lethal malignancies worldwide despite the use of various therapeutic strategies.A better understanding of the mechanisms responsible for tumor initiation and progression is essential for the development of novel,more powerful therapies.The traditional,so-called'stochastic model'of tumor development,which assumes that each cancer cell is tumorigenic,has been deeply challenged during the past decade by the identification of cancer stem cells(CSCs),a biologically distinct subset of cells within the bulk of tumor mass.This discovery led to the development of the hierarchical model of tumorigenesis which assumes that only CSCs have the ability to initiate tumor growth,both at primary and metastatic sites.This model implies that the elimination of all CSCs is fundamental to eradicate tumors and that failure to do so might be responsible for the occurrence of relapses and/or metastases frequently observed in the clinical management of colorectal cancer patients.Identification and isolation of CSCs is essential for a better understanding of their role in the tumorigenetic process and for the development of CSC-specific therapies.Several methods have been used for this purpose and many efforts have been focused on the identification of specific CSC-surface markers.This review provides an overview of the proposed roles of CSC in human colorectal tumorigenesis focusing on the most important molecules identified as CSC-specific markers in colorectal cancer and on the potential strategies for the development of CSC-targeted therapy. | Caterina Fanali Donatella Lucchetti Marisa Farina Maddalena Corbi Valerio Cufino Achille Cittadini Alessandro Sgambato | 2014 | World Journal of Gastroenterology2014，20，4： | 7 |
| 2 | Relative dominance of gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control显示文摘 | Lucchetti A Galvan P | 2006 | J Virol2006，80，6： | 1 |
| 3 | Immunosuppmssive and anti-inflammatory effects of methanolic extract and the polyacetylene isolated from Bidens pilosa L 显示文摘 | Pereira R L Ibrahim T Lucchetti L | 1999 | Immunopharmacology1999，43，1： | 1 |
| 4 | A randomized trial of tranexamic acid in combination with cell salvage plus a meta-analysis of randomized trials evaluating tranexamic acid in off-pump coronary artery bypass grafting 显示文摘 | Murphy GJ Mango E Lucchetti V | 2006 | J Thorac Cardiovasc Surg2006，132，3： | 1 |
| 5 | A characterization of Tykhonov well-posedness for minimum problems with applications to variational inequalities显示文摘 | Lucchetti R Patrone F | 1981 | Numer Funct Anal Optim1981，3，4： | 1 |
| 6 | Coronary artery bypass grafting in the awake patient:combined thoracic epidural and lumbar subarachnoid block显示文摘 | Lucchetti V Moscariello C Catapano D | 2004 | Eur J Cardiothorac Surg2004，26，3： | 1 |
| 7 | Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines显示文摘 | Davide Ferrari Sara Gulinelli Valentina Salvestrini Giovanna Lucchetti Roberta Zini Rossella Manfredini Luisa Caione Wanda Piacibello Marilena Ciciarello Lara Rossi Marco Idzko Sergio Ferrari Francesco Di Virgilio Roberto M. Lemoli | 2011 | Experimental Hematology2011，，3： | 1 |
| 8 | A randomized trial of tranexamic acid in combination with cell salvage plus a meta analysis of randomized trials evaluating tranexamic acid in off-pump coronary artery bypass grafting显示文摘 | Murphy GJ Mango E Lucchetti V | 2006 | J Thorac Cardiovasc Sur2006，132，3： | 1 |
| 9 | Uniform convergence of probability measures : topological criteria 显示文摘 | Lucchetti R Salinetti G Wets J B | 1994 | Journal of Multivariates Analysis1994，，51： | 1 |
| 10 | Environmental policy, innovation and performance: new insights on the Porter hypothesis显示文摘 | Lanoie P Laurent - Lucchetti J Johnstone N | 2011 | Journal of Econom- ics & Management Strategy2011，20，3： | 1 |
| 11 | Gastric Cancer surveillance in a high-risk population in Tuscany(Central Italy): preliminary results显示文摘 | Filomena A Saieva C Lucchetti V | 2011 | Digestion2011，84，1： | 1 |
| 12 | Uniform convergence of probability measures:topological criteria显示文摘 | Lucchetti R Salinetti G Wets R J B | 1994 | Journal of Multivariate Analysis1994，，51： | 1 |
| 13 | Gastric Cancer surveiliance in a high-risk population in Tuscany(Central Italy):preliminary results显示文摘 | Filomena A Saieva C Lucchetti V | 2011 | Digestion2011，84，1： | 1 |
| 14 | Gastric Cancer surveillance in a high-risk population in Tuscany(Central Italy) : preliminary results 显示文摘 | Filomena A Saieva C Lucchetti V | 2011 | Digestion2011，84，1： | 1 |
| 15 | Relative dominance of Gag p24-speciflc cytotoxic T lymphocytes is associated with human immunodeficiency virus control显示文摘 | Zuniga R Lucchetti A Galvan P | 2006 | J Viral2006，80，6： | 1 |
| 16 | Clinical significance of glycemic parameters on venous thromboembolism risk prediction in gastrointestinal cancer显示文摘AIM To investigate the possible predictive role of routinely used glycemic parameters for a first venous thromboembolism(VTE) episode in gastrointestinal(GI) cancer ambulatory patients-with or without clinically diagnosed type 2 diabetes(T2D) or obesity-treated with chemotherapy.METHODS Pre-treatment fasting blood glucose,insulin,glycated hemoglobin(Hb A1c) and homeostasis model of risk assessment(HOMA) were retrospectively evaluated in a cohort study of 342 GI cancer patients. Surgery was performed in 142(42%) patients with primary cancer,30(21%) and 112(79%) of whom received neoadjuvant and adjuvant therapies,respectively. Firstline chemotherapy was administered in 200(58%) patients with metastatic disease. The study outcome was defined as the occurrence of a first symptomatic or asymptomatic VTE episode during active treatment.RESULTS Impaired glucose tolerance(IGT) or T2 D were diagnosed in 30% of GI cancer patients,while overweight/obesity had an incidence of 41%. VTE occurred in 9.4% of patients(7% of non-diabetic non-obese),especially in those with a high ECOG score(P = 0.025). No significant association was found between VTE incidence and T2 D,obesity,different tumor types,metastatic disease,Khorana class of risk,or different anti-cancer drugs,although VTE rates were substantially higher in patients receiving bevacizumab(17% vs 8%,P = 0.044). Conversely,all glucose metabolic indexes were associated with increased VTE risk at ROC analysis. Multivariate Cox proportional analyses confirmed that HOMA index(HR = 4.13,95%CI: 1.63-10.5) or fasting blood glucose(HR = 3.56,95%CI: 1.51-8.39) were independent predictors of VTE occurrence during chemotherapy.CONCLUSION The results here reported demonstrate that evaluating glucose metabolic asset may allow for VTE risk stratification in GI cancer,helping to identify chemotherapy-treated patients who might benefit from thromboprophylaxis. Further multicenter prospective studies involving a larger number of patients are presently needed. | Fiorella Guadagni Silvia Riondino Vincenzo Formica Girolamo Del Monte Anna Maria Morelli Jessica Lucchetti Antonella Spila Roberta D’Alessandro David Della-Morte Patrizia Ferroni Mario Roselli | 2017 | World Journal of Gastroenterology2017，23，28： | 1 |
| 17 | Existence Theorems of Equilibrium Points in Stackelberg显示文摘 | Lucchetti R Mignanego F Pieri G | 1987 | Optimization1987，18，6： | 1 |
| 18 | Spiritist psychiatric hospitals in Brazil:integration of conventional psychiatric treatment and spiritual complementary therapy显示文摘 | Lucchetti G Aguiar PR Braghetta CC | | 0，，01： | 1 |
| 19 | Nursing home care: exploring the role of religiousness in the mental health, quality of life and stress of formal caregivers显示文摘 | G. Lucchetti A. L. G. Lucchetti G. R. Oliveira D. Crispim S. L. Pires M. L. Gorzoni C. R. G. Panicio H. G. Koenig | 2014 | J Psychiatr Ment Health Nurs2014，，5： | 1 |
| 20 | Long depletion time of enrofloxacin in rainbow trout (Oncorhynchus mykiss)显示文摘 | Lucchetti D Fabrizi L Guandalini E | 2004 | Antimicrob Agents Chemother2004，48，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员